LCM
VRNA

Legato Capital Management’s Verona Pharma VRNA Stock Holding History

Legato Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,213
Closed -$3.24M – 628
2025
Q2 		$3.24M Buy
34,213
+8,482
+33% +$628K 0.39% 56
2025
Q1 		$1.63M Buy
25,731
+878
+4% +$52.5K 0.22% 141
2024
Q4 		$1.15M Buy
24,853
+14,183
+133% +$532K 0.15% 254
2024
Q3 		$307K Hold
10,670
– – 0.04% 509
2024
Q2 		$154K Buy
+10,670
New +$156K 0.02% 526
2024
Q1 		– Sell
-24,329
Closed -$484K – 619
2023
Q4 		$484K Buy
24,329
+5,032
+26% +$74.3K 0.06% 424
2023
Q3 		$315K Hold
19,297
– – 0.05% 471
2023
Q2 		$408K Buy
+19,297
New +$412K 0.06% 459

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Legato Capital Management's VRNA Position: Q3 2025 in Review

Legato Capital Management sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 34,213 shares — an estimated $3.24M sold.

Legato Capital Management first reported a position in VRNA in Q2 2023 and held it in 8 quarters. The position peaked at $3.24M in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Legato Capital Management reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Legato Capital Management sold 34,213 Verona Pharma shares in Q3 2025, an estimated $3.24M.
  • Legato Capital Management first reported a position in Verona Pharma in Q2 2023 and held it in 8 quarters.
  • Legato Capital Management's Verona Pharma position peaked at $3.24M in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Legato Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.